糖尿病护理药物市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按药物(口服抗糖尿病药物、胰岛素、非胰岛素注射药物和组合药物)和地理划分。

市场快照

Diabetes Drugs Market Size
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >4 %
Diabetes Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

糖尿病护理药物市场在 2019 年达到 697 亿美元,预计在预测期间(2020-2025 年)的复合年增长率将超过 4.5%。

  • 市场的显着增长可归因于诸如糖尿病患病率上升以及各种健康组织发起的与健康意识相关的计划数量增加等因素。目前,大约 10% 的糖尿病病例为 1 型,其余为 2 型。
  • 截至 2019 年,北美占市场的主要份额,其次是亚太地区。糖尿病患者人数的增加主要是由于不健康的饮食和久坐不动的生活方式导致人们肥胖的增加。亚太市场主要受中国和印度对糖尿病药物需求增长的推动。目前,中国有超过1.2亿糖尿病患者,而印度的糖尿病患者人数预计到2025年将达到8700万。
  • 基于药物,胰岛素部分在市场上占有重要份额。全世界有超过 1 亿人需要胰岛素,包括所有 1 型糖尿病患者和 10% 至 25% 的 2 型糖尿病患者。

报告范围

糖尿病或糖尿病描述了一组以人体内高血糖水平为特征的代谢紊乱。对于糖尿病,身体要么不能产生足够的胰岛素,要么身体的细胞不能对胰岛素做出适当的反应,或者两者兼而有之。糖尿病护理药物市场按药物细分为胰岛素(基础或长效、推注或速效、传统人胰岛素药物和胰岛素生物仿制药)、口服抗糖尿病药物(α-葡萄糖苷酶抑制剂、DPP-4 抑制剂、和 SGLT-2 抑制剂)、非胰岛素注射药物(GLP-1 受体激动剂和胰淀素类似物)和组合药物(组合胰岛素、口服组合)。

By Drugs
Oral Anti-diabetic drugs (Value and Volume 2012-2024)
Biguanides
Metformin
Alpha-glucosidase Inhibitors
Dopamine -D2 Receptor Agonist
Cycloset (Bromocriptin)
Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Meglitinides
Insulin (Value and Volume 2012-2025)
Basal or Long-acting Insulin
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulin
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulin
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulin
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Non-insulin Injectable Drug (Value and Volume 2012-2025)
GLP-1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination Drug
Combination Insulin
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin HCl)
Geography
North America
United States (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Canada (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Rest of North America (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Europe
France (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Germany (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Italy (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Spain (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
United Kingdom (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Russia (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Rest of Europe (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Latin America
Mexico (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Brazil (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Rest of Latin America (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Asia-Pacific
Japan (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
South Korea (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
China (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
India (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Australia (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Vietnam (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Malaysia (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Indonesia (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Philippines (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Thailand (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Rest of Asia-Pacific (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Middle-East and Africa
Saudi Arabia (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Iran (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Egypt (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Oman (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
South Africa (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
Rest of Middle-East and Africa (Value and Volume 2012-2025)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs

Report scope can be customized per your requirements. Click here.

主要市场趋势

2019年胰岛素药物占糖尿病护理药物市场近25%的市场份额

在预测期内,胰岛素部分预计将以超过 2.5% 的复合年增长率增长,这主要是由于 1 型糖尿病人群的需求,到 2019 年底超过 3000 万。一些 2 型糖尿病患者也依赖胰岛素​​。虽然只有 10% 的糖尿病人群是 1 型,但他们的胰岛素摄入量更高。对胰岛素的需求是由于人们对胰岛素对糖尿病患者益处的认识提高,尤其是在新兴经济体。其他因素,例如胰岛素输送系统的快速发展、主要公司的药物和类似物开发,以及老年人和肥胖人口的增加,可能会推动胰岛素市场的增长。2019年,在胰岛素药物领域,基础胰岛素在整个糖尿病护理药物市场中占据 46% 的市场份额和 13% 以上的市场份额。根据国际糖尿病联合会的数据,2019 年糖尿病患者花费了 7600 亿美元,其中很大一部分是 1 型糖尿病患者在胰岛素药物上的花费。

Diabetes Drugs Market Trends

2019 年北美和亚太地区合计占市场份额的 60% 以上

北美在 2019 年录得超过 290 亿美元的收入,预计在预测期内将以超过 4% 的复合年增长率进一步增长。这主要是由于压力、不健康的饮食和肥胖导致北美糖尿病人口的增加。在北美,有超过 2900 万糖尿病患者,预计到 2025 年这一数字将增加到 3200 万。仅美国在 2019 年就记录了超过 2500 万糖尿病患者。在北美,美国占有主要份额在糖尿病护理药物市场。有利的政府报销政策和先进的医疗基础设施也支持该地区糖尿病药物市场的增长。东南亚国家预计将在未来几年产生更高的需求,主要是由于当地政府和卫生组织采取的旨在传播对糖尿病、药物和设备的认识的举措。在过去十年中,该地区的糖尿病人口以惊人的速度增长。亚太地区新兴经济体糖尿病药物市场面临的主要挑战是缺乏医疗基础设施和集中供应链,导致价格波动。

Diabetes Drugs Market Growth

竞争格局

糖尿病药物市场适度分散,很少有重要的和通用的参与者。胰岛素药物和 Sglt-2 药物市场由少数主要参与者主导,如 Novo-Nordisk、Sanofi、AstraZeneca 和 Bristol Myers Squibb。口服药物市场,如磺脲类和氯茴苯酸类药物,包括更多的仿制药参与者。参与者之间的竞争激烈,因为每个参与者都在努力开发新药并以有竞争力的价格提供。此外,为了增加市场份额,参与者正在开拓新市场,特别是需求与供应相比非常高的新兴经济体。糖尿病护理药物市场的一些最新发展包括:

  • 2020年1月,美国FDA批准Trijardy XR(恩格列净/利格列汀/盐酸二甲双胍缓释片)用于降低成人2型糖尿病患者的血糖。Trijardy XR 在一颗药丸中提供三种 2 型糖尿病药物。
  • 2019年9月,诺和诺德宣布美国FDA已批准Rybelsus(semaglutide)口服片剂用于成年2型糖尿病患者。此次获批后,Rybelsus 成为美国首个获批使用的胰高血糖素样肽(GLP-1)受体蛋白治疗药物,无需注射。
  • 2019年3月,诺和诺德宣布计划投资约9800万美元升级和扩建位于丹麦卡伦堡的胰岛素药物生产设施。该项目计划于2020年底前完成。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drugs

      1. 5.1.1 Oral Anti-diabetic drugs (Value and Volume 2012-2024)

        1. 5.1.1.1 Biguanides

          1. 5.1.1.1.1 Metformin

        2. 5.1.1.2 Alpha-glucosidase Inhibitors

        3. 5.1.1.3 Dopamine -D2 Receptor Agonist

          1. 5.1.1.3.1 Cycloset (Bromocriptin)

        4. 5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors

          1. 5.1.1.4.1 Invokana (Canagliflozin)

          2. 5.1.1.4.2 Jardiance (Empagliflozin)

          3. 5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)

          4. 5.1.1.4.4 Suglat (Ipragliflozin)

        5. 5.1.1.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

          1. 5.1.1.5.1 Januvia (Sitagliptin)

          2. 5.1.1.5.2 Onglyza (Saxagliptin)

          3. 5.1.1.5.3 Tradjenta (Linagliptin)

          4. 5.1.1.5.4 Vipidia/Nesina (Alogliptin)

          5. 5.1.1.5.5 Galvus (Vildagliptin)

        6. 5.1.1.6 Sulfonylureas

        7. 5.1.1.7 Meglitinides

      2. 5.1.2 Insulin (Value and Volume 2012-2025)

        1. 5.1.2.1 Basal or Long-acting Insulin

          1. 5.1.2.1.1 Lantus (Insulin Glargine)

          2. 5.1.2.1.2 Levemir (Insulin Detemir)

          3. 5.1.2.1.3 Toujeo (Insulin Glargine)

          4. 5.1.2.1.4 Tresiba (Insulin Degludec)

          5. 5.1.2.1.5 Basaglar (Insulin Glargine)

        2. 5.1.2.2 Bolus or Fast-acting Insulin

          1. 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.2.2.2 Humalog (Insulin Lispro)

          3. 5.1.2.2.3 Apidra (Insulin Glulisine)

        3. 5.1.2.3 Traditional Human Insulin

          1. 5.1.2.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.2.3.2 Humulin

          3. 5.1.2.3.3 Insuman

        4. 5.1.2.4 Biosimilar Insulin

          1. 5.1.2.4.1 Insulin Glargine Biosimilars

          2. 5.1.2.4.2 Human Insulin Biosimilars

      3. 5.1.3 Non-insulin Injectable Drug (Value and Volume 2012-2025)

        1. 5.1.3.1 GLP-1 Receptor Agonists

          1. 5.1.3.1.1 Victoza (Liraglutide)

          2. 5.1.3.1.2 Byetta (Exenatide)

          3. 5.1.3.1.3 Bydureon (Exenatide)

          4. 5.1.3.1.4 Trulicity (Dulaglutide)

          5. 5.1.3.1.5 Lyxumia (Lixisenatide)

        2. 5.1.3.2 Amylin Analogue

          1. 5.1.3.2.1 Symlin (Pramlintide)

      4. 5.1.4 Combination Drug

        1. 5.1.4.1 Combination Insulin

          1. 5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)

          2. 5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

        2. 5.1.4.2 Oral Combination

          1. 5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume 2012-2025)

          1. 5.2.1.1.1 Oral Anti-diabetic Drugs

          2. 5.2.1.1.2 Insulin

          3. 5.2.1.1.3 Non-insulin Injectable Drugs

          4. 5.2.1.1.4 Combination Drugs

        2. 5.2.1.2 Canada (Value and Volume 2012-2025)

          1. 5.2.1.2.1 Oral Anti-diabetic Drugs

          2. 5.2.1.2.2 Insulin

          3. 5.2.1.2.3 Non-insulin Injectable Drugs

          4. 5.2.1.2.4 Combination Drugs

        3. 5.2.1.3 Rest of North America (Value and Volume 2012-2025)

          1. 5.2.1.3.1 Oral Anti-diabetic Drugs

          2. 5.2.1.3.2 Insulin

          3. 5.2.1.3.3 Non-insulin Injectable Drugs

          4. 5.2.1.3.4 Combination Drugs

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume 2012-2025)

          1. 5.2.2.1.1 Oral Anti-diabetic Drugs

          2. 5.2.2.1.2 Insulin

          3. 5.2.2.1.3 Non-insulin Injectable Drugs

          4. 5.2.2.1.4 Combination Drugs

        2. 5.2.2.2 Germany (Value and Volume 2012-2025)

          1. 5.2.2.2.1 Oral Anti-diabetic Drugs

          2. 5.2.2.2.2 Insulin

          3. 5.2.2.2.3 Non-insulin Injectable Drugs

          4. 5.2.2.2.4 Combination Drugs

        3. 5.2.2.3 Italy (Value and Volume 2012-2025)

          1. 5.2.2.3.1 Oral Anti-diabetic Drugs

          2. 5.2.2.3.2 Insulin

          3. 5.2.2.3.3 Non-insulin Injectable Drugs

          4. 5.2.2.3.4 Combination Drugs

        4. 5.2.2.4 Spain (Value and Volume 2012-2025)

          1. 5.2.2.4.1 Oral Anti-diabetic Drugs

          2. 5.2.2.4.2 Insulin

          3. 5.2.2.4.3 Non-insulin Injectable Drugs

          4. 5.2.2.4.4 Combination Drugs

        5. 5.2.2.5 United Kingdom (Value and Volume 2012-2025)

          1. 5.2.2.5.1 Oral Anti-diabetic Drugs

          2. 5.2.2.5.2 Insulin

          3. 5.2.2.5.3 Non-insulin Injectable Drugs

          4. 5.2.2.5.4 Combination Drugs

        6. 5.2.2.6 Russia (Value and Volume 2012-2025)

          1. 5.2.2.6.1 Oral Anti-diabetic Drugs

          2. 5.2.2.6.2 Insulin

          3. 5.2.2.6.3 Non-insulin Injectable Drugs

          4. 5.2.2.6.4 Combination Drugs

        7. 5.2.2.7 Rest of Europe (Value and Volume 2012-2025)

          1. 5.2.2.7.1 Oral Anti-diabetic Drugs

          2. 5.2.2.7.2 Insulin

          3. 5.2.2.7.3 Non-insulin Injectable Drugs

          4. 5.2.2.7.4 Combination Drugs

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume 2012-2025)

          1. 5.2.3.1.1 Oral Anti-diabetic Drugs

          2. 5.2.3.1.2 Insulin

          3. 5.2.3.1.3 Non-insulin Injectable Drugs

          4. 5.2.3.1.4 Combination Drugs

        2. 5.2.3.2 Brazil (Value and Volume 2012-2025)

          1. 5.2.3.2.1 Oral Anti-diabetic Drugs

          2. 5.2.3.2.2 Insulin

          3. 5.2.3.2.3 Non-insulin Injectable Drugs

          4. 5.2.3.2.4 Combination Drugs

        3. 5.2.3.3 Rest of Latin America (Value and Volume 2012-2025)

          1. 5.2.3.3.1 Oral Anti-diabetic Drugs

          2. 5.2.3.3.2 Insulin

          3. 5.2.3.3.3 Non-insulin Injectable Drugs

          4. 5.2.3.3.4 Combination Drugs

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume 2012-2025)

          1. 5.2.4.1.1 Oral Anti-diabetic Drugs

          2. 5.2.4.1.2 Insulin

          3. 5.2.4.1.3 Non-insulin Injectable Drugs

          4. 5.2.4.1.4 Combination Drugs

        2. 5.2.4.2 South Korea (Value and Volume 2012-2025)

          1. 5.2.4.2.1 Oral Anti-diabetic Drugs

          2. 5.2.4.2.2 Insulin

          3. 5.2.4.2.3 Non-insulin Injectable Drugs

          4. 5.2.4.2.4 Combination Drugs

        3. 5.2.4.3 China (Value and Volume 2012-2025)

          1. 5.2.4.3.1 Oral Anti-diabetic Drugs

          2. 5.2.4.3.2 Insulin

          3. 5.2.4.3.3 Non-insulin Injectable Drugs

          4. 5.2.4.3.4 Combination Drugs

        4. 5.2.4.4 India (Value and Volume 2012-2025)

          1. 5.2.4.4.1 Oral Anti-diabetic Drugs

          2. 5.2.4.4.2 Insulin

          3. 5.2.4.4.3 Non-insulin Injectable Drugs

          4. 5.2.4.4.4 Combination Drugs

        5. 5.2.4.5 Australia (Value and Volume 2012-2025)

          1. 5.2.4.5.1 Oral Anti-diabetic Drugs

          2. 5.2.4.5.2 Insulin

          3. 5.2.4.5.3 Non-insulin Injectable Drugs

          4. 5.2.4.5.4 Combination Drugs

        6. 5.2.4.6 Vietnam (Value and Volume 2012-2025)

          1. 5.2.4.6.1 Oral Anti-diabetic Drugs

          2. 5.2.4.6.2 Insulin

          3. 5.2.4.6.3 Non-insulin Injectable Drugs

          4. 5.2.4.6.4 Combination Drugs

        7. 5.2.4.7 Malaysia (Value and Volume 2012-2025)

          1. 5.2.4.7.1 Oral Anti-diabetic Drugs

          2. 5.2.4.7.2 Insulin

          3. 5.2.4.7.3 Non-insulin Injectable Drugs

          4. 5.2.4.7.4 Combination Drugs

        8. 5.2.4.8 Indonesia (Value and Volume 2012-2025)

          1. 5.2.4.8.1 Oral Anti-diabetic Drugs

          2. 5.2.4.8.2 Insulin

          3. 5.2.4.8.3 Non-insulin Injectable Drugs

          4. 5.2.4.8.4 Combination Drugs

        9. 5.2.4.9 Philippines (Value and Volume 2012-2025)

          1. 5.2.4.9.1 Oral Anti-diabetic Drugs

          2. 5.2.4.9.2 Insulin

          3. 5.2.4.9.3 Non-insulin Injectable Drugs

          4. 5.2.4.9.4 Combination Drugs

        10. 5.2.4.10 Thailand (Value and Volume 2012-2025)

          1. 5.2.4.10.1 Oral Anti-diabetic Drugs

          2. 5.2.4.10.2 Insulin

          3. 5.2.4.10.3 Non-insulin Injectable Drugs

          4. 5.2.4.10.4 Combination Drugs

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2025)

          1. 5.2.4.11.1 Oral Anti-diabetic Drugs

          2. 5.2.4.11.2 Insulin

          3. 5.2.4.11.3 Non-insulin Injectable Drugs

          4. 5.2.4.11.4 Combination Drugs

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume 2012-2025)

          1. 5.2.5.1.1 Oral Anti-diabetic Drugs

          2. 5.2.5.1.2 Insulin

          3. 5.2.5.1.3 Non-insulin Injectable Drugs

          4. 5.2.5.1.4 Combination Drugs

        2. 5.2.5.2 Iran (Value and Volume 2012-2025)

          1. 5.2.5.2.1 Oral Anti-diabetic Drugs

          2. 5.2.5.2.2 Insulin

          3. 5.2.5.2.3 Non-insulin Injectable Drugs

          4. 5.2.5.2.4 Combination Drugs

        3. 5.2.5.3 Egypt (Value and Volume 2012-2025)

          1. 5.2.5.3.1 Oral Anti-diabetic Drugs

          2. 5.2.5.3.2 Insulin

          3. 5.2.5.3.3 Non-insulin Injectable Drugs

          4. 5.2.5.3.4 Combination Drugs

        4. 5.2.5.4 Oman (Value and Volume 2012-2025)

          1. 5.2.5.4.1 Oral Anti-diabetic Drugs

          2. 5.2.5.4.2 Insulin

          3. 5.2.5.4.3 Non-insulin Injectable Drugs

          4. 5.2.5.4.4 Combination Drugs

        5. 5.2.5.5 South Africa (Value and Volume 2012-2025)

          1. 5.2.5.5.1 Oral Anti-diabetic Drugs

          2. 5.2.5.5.2 Insulin

          3. 5.2.5.5.3 Non-insulin Injectable Drugs

          4. 5.2.5.5.4 Combination Drugs

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume 2012-2025)

          1. 5.2.5.6.1 Oral Anti-diabetic Drugs

          2. 5.2.5.6.2 Insulin

          3. 5.2.5.6.3 Non-insulin Injectable Drugs

          4. 5.2.5.6.4 Combination Drugs

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2012-2025)

    2. 6.2 Type-2 Diabetes Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Vendor Market Share

    2. 7.2 Company Profiles

      1. 7.2.1 Novo Nordisk

      2. 7.2.2 Sanofi

      3. 7.2.3 Eli Lilly and Company

      4. 7.2.4 Biocon

      5. 7.2.5 AstraZeneca

      6. 7.2.6 Bristol Myers Squibb

      7. 7.2.7 Boehringer Ingelheim

      8. 7.2.8 Mylan

      9. 7.2.9 Pfizer

      10. 7.2.10 Johnson & Johnson

      11. 7.2.11 Merck & Co.

      12. 7.2.12 Novartis

      13. 7.2.13 Astellas Pharma

      14. 7.2.14 Teva Pharmaceuticals

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Diabetes Care Drugs Market market is studied from 2016 - 2027.

The Diabetes Care Drugs Market is growing at a CAGR of >4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company are the major companies operating in Diabetes Care Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!